Wird geladen...
Biosimilars: Key regulatory considerations and similarity assessment tools
A biosimilar drug is defined in the US Food and Drug Administration (FDA) guidance document as a biopharmaceutical that is highly similar to an already licensed biologic product (referred to as the reference product) notwithstanding minor differences in clinically inactive components and for which t...
Gespeichert in:
| Veröffentlicht in: | Biotechnol Bioeng |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5698755/ https://ncbi.nlm.nih.gov/pubmed/28842986 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bit.26438 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|